SNY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 2NCT05039840Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSanofi · Systemic Lupus ErythematosusActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Sep 4, 2026Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07905534A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic...Sanofi · Atherosclerotic Cardiovascular DiseaseActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Aug 21, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05831176A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic...Regeneron Pharmaceuticals · Eosinophilic Gastritis (EoG)Active, not recruitingREGNLeadSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 23, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanSanofi · Immune ThrombocytopeniaActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07457580Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)Sanofi · Type 1 DiabetesRecruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT01973881Quantitative MRI for MyelofibrosisUniversity of Michigan Rogel Cancer Center · MyelofibrosisRecruitingSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06352073Dupilumab for Eosinophilic Esophagitis With Severe StricturesUniversity of North Carolina, Chapel Hill · Eosinophilic EsophagitisActive, not recruitingREGNCollaboratorSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Apr 16, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06838000Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy...Sanofi Pasteur, a Sanofi Company · Pneumococcal InfectionsActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06907511Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic...Sanofi · Pandemic Influenza ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05588843Dose-finding Study of SAR443122 in Adult Participants With Ulcerative ColitisSanofi · Colitis UlcerativeActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Feb 10, 2026Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT04743609RSV Burden in Outpatient and Hospital SettingsAssociation Clinique Thérapeutique Infantile du val de Marne · RSV InfectionRecruitingSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06137261Screening Adults With Obesity to Reduce Heart Failure EventsFranciscus Gasthuis · ObesityActive, not recruitingNVOCollaboratorSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05950750Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter StudyTurkish Hematology Association · TTP - Thrombotic Thrombocytopenic PurpuraRecruitingSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 21, 2023Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04430894KRDI in Transplant-Eligible MMMassachusetts General Hospital · Multiple MyelomaActive, not recruitingAMGNCollaboratorSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 30, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02425904Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related DisordersDana-Farber Cancer Institute · Langerhans Cell HistiocytosisActive, not recruitingSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 2020Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06258057Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During PregnancySanofi · Pertussis (Whooping Cough)Active, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05206773A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age...Sanofi · Fabry DiseaseActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 17, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi · Sickle Cell DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Jan 7, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04644575Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia ABioverativ, a Sanofi company · Hemophilia AActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Jan 15, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06686654Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based...Sanofi Pasteur, a Sanofi Company · Human Metapneumovirus ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Jan 18, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07726914Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsSanofi · Chronic Graft Versus Host DiseaseNot yet recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Jan 26, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07861542Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19Sanofi · COVID-19Active, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Nov 26, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05668013A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's DiseaseTeva Branded Pharmaceutical Products R&D LLC · Crohn DiseaseActive, not recruitingSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 5, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06834360A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 24, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07424144An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 17, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.